Investigational drug · Phase 2
Casdozokitug
Also called: CHS-388
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Casdozokitug"
First trial start
2024
Dec 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Casdozokitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Casdozokitug" as an intervention, largest first.
Coherus Oncology, Inc.Industry
NCT04374877 · 145 participants · Start Apr 22, 2020 · Primary completion May 28, 2025
Drug: CHS-388; Pembrolizumab and 1 more · For: Advanced Solid Tumor; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma and 1 more
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 23 sites in all
- A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaActive, not recruiting
Coherus Oncology, Inc.Industry
NCT06679985 · 72 participants (planned) · Start Dec 20, 2024 · Primary completion Sep 2027
Drug: Casdozokitug; Toripalimab and 1 more · For: Hepatocellular Carcinoma
Sites: Scottsdale, Arizona; Tucson, Arizona; Beverly Hills, California · 44 sites in all
Coherus Oncology, Inc.Industry
NCT05359861 · 30 participants · Start Apr 12, 2022 · Primary completion Jun 30, 2025
Drug: Casdozokitug; Atezolizumab and 2 more · For: Hepatocellular Carcinoma
Sites: Tucson, Arizona; Duarte, California; Los Angeles, California · 37 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.